Symbols / DAWN
DAWN Chart
About
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.18B |
| Enterprise Value | 785.47M | Income | -151.76M | Sales | 133.67M |
| Book/sh | 4.39 | Cash/sh | 4.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 184 | IPO | — |
| P/E | — | Forward P/E | 142.93 | PEG | — |
| P/S | 8.83 | P/B | 2.62 | P/C | — |
| EV/EBITDA | -4.84 | EV/Sales | 5.88 | Quick Ratio | 8.29 |
| Current Ratio | 8.68 | Debt/Eq | 0.64 | LT Debt/Eq | — |
| EPS (ttm) | -1.52 | EPS next Y | 0.08 | EPS Growth | — |
| Revenue Growth | -57.60% | Earnings | 2026-05-05 | ROA | -18.58% |
| ROE | -30.16% | ROIC | — | Gross Margin | 89.44% |
| Oper. Margin | -60.94% | Profit Margin | -113.53% | Shs Outstand | 102.68M |
| Shs Float | 73.71M | Short Float | 14.73% | Short Ratio | 3.71 |
| Short Interest | — | 52W High | 13.20 | 52W Low | 5.63 |
| Beta | -1.26 | Avg Volume | 2.55M | Volume | 642.59K |
| Target Price | $23.12 | Recom | Buy | Prev Close | $12.02 |
| Price | $11.50 | Change | -4.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.13
Mean price target
2. Current target
$11.50
Latest analyst target
3. DCF / Fair value
$-10.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.50
Low
$17.00
High
$29.00
Mean
$23.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | main | Wedbush | Outperform → Outperform | $30 |
| 2026-02-25 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2026-02-25 | main | Needham | Buy → Buy | $17 |
| 2026-01-13 | init | TD Cowen | — → Buy | $34 |
| 2025-11-24 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-24 | reit | Needham | Buy → Buy | $16 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $27 |
| 2025-11-05 | main | Piper Sandler | Overweight → Overweight | $26 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-06 | main | Needham | Buy → Buy | $16 |
| 2025-05-07 | main | Needham | Buy → Buy | $27 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-03-25 | main | Goldman Sachs | Buy → Buy | $27 |
| 2025-03-05 | main | JP Morgan | Overweight → Overweight | $34 |
| 2025-02-26 | reit | Wedbush | Outperform → Outperform | $32 |
| 2025-02-26 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-02-26 | reit | Needham | Buy → Buy | $32 |
| 2025-02-10 | main | Goldman Sachs | Buy → Buy | $43 |
| 2025-01-13 | reit | Needham | Buy → Buy | $33 |
| 2025-01-07 | main | B of A Securities | Buy → Buy | $25 |
- Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 25 Feb 2026 00
- Needham lowers Day One Biopharmaceuticals price target on costs - Investing.com Wed, 25 Feb 2026 13
- A Look At Day One Biopharmaceuticals (DAWN) Valuation As Earnings Expectations Build For February 2026 - simplywall.st ue, 24 Feb 2026 17
- Why (DAWN) Price Action Is Critical for Tactical Trading - Stock Traders Daily ue, 24 Feb 2026 03
- SNAP’s False Revenue Dawn Leaves Stock With Bearish Bias - TipRanks Sat, 21 Feb 2026 01
- A New Dawn for Non-US Stocks? Rethinking Global Equity Allocations - AllianceBernstein Fri, 23 Jan 2026 08
- ECC revises sale price for Passco wheat stock - Dawn Wed, 25 Feb 2026 02
- $DAWN stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 08 Dec 2025 08
- Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - Nasdaq hu, 30 Oct 2025 07
- Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish (NASDAQ:DAWN) - Seeking Alpha hu, 18 Dec 2025 08
- Trump Offers New Dawn For Solar Stocks. This Is The Next Growth Driver. - Investor's Business Daily Wed, 10 Sep 2025 07
- Examining Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Moves And OJEMDA Growth Expectations - Yahoo Finance Sat, 14 Feb 2026 08
- Day one Biopharma CCO sold $67k in DAWN stock By Investing.com - Investing.com Canada hu, 19 Feb 2026 07
- IREN: The Dark Before The AI Dawn (NASDAQ:IREN) - Seeking Alpha Wed, 18 Feb 2026 14
- $DAWN stock is down 13% today. Here's what we see in our data. - Quiver Quantitative hu, 13 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6065 | 70359.0 | — | Sale at price 11.60 per share. | YORK CHARLES N. II CPA | Chief Operating Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 2728 | 31647.0 | — | Sale at price 11.60 per share. | VASCONCELLES MICHAEL | Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 6395 | 74188.0 | — | Sale at price 11.60 per share. | DUBOW ADAM | General Counsel | — | 2026-02-17 00:00:00 | D |
| 3 | 5814 | 67448.0 | — | Sale at price 11.60 per share. | MERENDINO LAUREN | Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 15459 | 179338.0 | — | Sale at price 11.60 per share. | BENDER JEREMY | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 5 | 23375 | nan | — | — | YORK CHARLES N. II CPA | Chief Operating Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 7125 | nan | — | — | VASCONCELLES MICHAEL | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 16463 | nan | — | — | DUBOW ADAM | General Counsel | — | 2026-02-13 00:00:00 | D |
| 8 | 15162 | nan | — | — | MERENDINO LAUREN | Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 42937 | nan | — | — | BENDER JEREMY | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 4.14M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -234.94M | -222.87M | -151.12M | -72.55M |
| TotalUnusualItems | 19.70M | 17.19M | 4.75M | 4.00K |
| TotalUnusualItemsExcludingGoodwill | 19.70M | 17.19M | 4.75M | 4.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -95.50M | -188.92M | -142.18M | -70.64M |
| ReconciledDepreciation | 2.03M | 383.00K | 531.00K | 199.00K |
| ReconciledCostOfRevenue | 5.28M | 0.00 | 0.00 | |
| EBITDA | -215.24M | -205.68M | -146.38M | -72.54M |
| EBIT | -217.27M | -206.06M | -146.91M | -72.74M |
| NetInterestIncome | 4.75M | 4.00K | ||
| NormalizedIncome | -111.06M | -206.10M | -146.93M | -70.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -95.50M | -188.92M | -142.18M | -70.64M |
| TotalExpenses | 348.43M | 206.06M | 146.91M | 72.74M |
| TotalOperatingIncomeAsReported | -217.27M | -206.06M | -146.91M | -72.74M |
| DilutedAverageShares | 93.23M | 79.77M | 65.47M | 36.96M |
| BasicAverageShares | 93.23M | 79.77M | 65.47M | 36.96M |
| DilutedEPS | -1.02 | -2.37 | -2.17 | -4.62 |
| BasicEPS | -1.02 | -2.37 | -2.17 | -4.62 |
| DilutedNIAvailtoComStockholders | -95.50M | -188.92M | -142.18M | -170.64M |
| NetIncomeCommonStockholders | -95.50M | -188.92M | -142.18M | -170.64M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 99.99M | |
| NetIncome | -95.50M | -188.92M | -142.18M | -70.64M |
| MinorityInterests | 0.00 | 0.00 | 2.11M | |
| NetIncomeIncludingNoncontrollingInterests | -95.50M | -188.92M | -142.18M | -72.75M |
| NetIncomeContinuousOperations | -95.50M | -188.92M | -142.18M | -72.75M |
| TaxProvision | 7.14M | 0.00 | 0.00 | |
| PretaxIncome | -88.35M | -188.92M | -142.18M | -72.75M |
| OtherIncomeExpense | 128.92M | 17.15M | 4.73M | -11.00K |
| OtherNonOperatingIncomeExpenses | 109.22M | -40.00K | -18.00K | -15.00K |
| GainOnSaleOfSecurity | 19.70M | 17.19M | 4.75M | 4.00K |
| NetNonOperatingInterestIncomeExpense | 4.75M | 4.00K | ||
| TotalOtherFinanceCost | -4.75M | -4.00K | ||
| OperatingIncome | -217.27M | -206.06M | -146.91M | -72.74M |
| OperatingExpense | 343.15M | 206.06M | 146.91M | 72.74M |
| ResearchAndDevelopment | 227.70M | 130.52M | 85.62M | 43.58M |
| SellingGeneralAndAdministration | 115.45M | 75.54M | 61.29M | 29.16M |
| GeneralAndAdministrativeExpense | 75.54M | 61.29M | 29.16M | |
| OtherGandA | 75.54M | 61.29M | 29.16M | |
| GrossProfit | 125.88M | 0.00 | 0.00 | |
| CostOfRevenue | 5.28M | 0.00 | 0.00 | |
| TotalRevenue | 131.16M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 131.16M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 101.12M | 87.23M | 73.46M | 61.95M |
| ShareIssued | 101.12M | 87.23M | 73.46M | 61.95M |
| TotalDebt | 2.60M | 408.00K | 813.00K | 220.00K |
| TangibleBookValue | 487.12M | 346.54M | 332.04M | 281.15M |
| InvestedCapital | 502.75M | 346.54M | 332.04M | 281.15M |
| WorkingCapital | 488.88M | 345.77M | 331.26M | 280.71M |
| NetTangibleAssets | 487.12M | 346.54M | 332.04M | 281.15M |
| CapitalLeaseObligations | 2.60M | 408.00K | 813.00K | 220.00K |
| CommonStockEquity | 502.75M | 346.54M | 332.04M | 281.15M |
| TotalCapitalization | 502.75M | 346.54M | 332.04M | 281.15M |
| TotalEquityGrossMinorityInterest | 502.75M | 346.54M | 332.04M | 281.15M |
| MinorityInterest | 0.00 | |||
| StockholdersEquity | 502.75M | 346.54M | 332.04M | 281.15M |
| GainsLossesNotAffectingRetainedEarnings | 84.00K | 9.00K | -71.00K | 0.00 |
| OtherEquityAdjustments | 84.00K | 9.00K | -71.00K | |
| RetainedEarnings | -554.08M | -458.58M | -269.67M | -127.49M |
| AdditionalPaidInCapital | 1.06B | 805.11M | 601.77M | 408.63M |
| CapitalStock | 10.00K | 9.00K | 7.00K | 6.00K |
| CommonStock | 10.00K | 9.00K | 7.00K | 6.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 80.04M | 29.51M | 17.02M | 8.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.59M | 0.00 | 408.00K | 16.00K |
| OtherNonCurrentLiabilities | 761.00K | |||
| NonCurrentDeferredLiabilities | 3.23M | 0.00 | ||
| NonCurrentDeferredRevenue | 3.23M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 2.59M | 0.00 | 408.00K | 16.00K |
| LongTermCapitalLeaseObligation | 2.59M | 0.00 | 408.00K | 16.00K |
| CurrentLiabilities | 73.45M | 29.51M | 16.61M | 8.66M |
| OtherCurrentLiabilities | 12.16M | 1.04M | 179.00K | 104.00K |
| CurrentDeferredLiabilities | 1.55M | 0.00 | ||
| CurrentDeferredRevenue | 1.55M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 10.00K | 408.00K | 405.00K | 204.00K |
| CurrentCapitalLeaseObligation | 10.00K | 408.00K | 405.00K | 204.00K |
| PayablesAndAccruedExpenses | 59.72M | 28.06M | 16.03M | 8.35M |
| CurrentAccruedExpenses | 56.46M | 25.48M | 15.77M | 6.61M |
| Payables | 3.26M | 2.58M | 260.00K | 1.74M |
| AccountsPayable | 3.26M | 2.58M | 260.00K | 1.74M |
| TotalAssets | 582.79M | 376.05M | 349.06M | 289.82M |
| TotalNonCurrentAssets | 20.46M | 774.00K | 1.19M | 453.00K |
| OtherNonCurrentAssets | 121.00K | 214.00K | 469.00K | 169.00K |
| NonCurrentPrepaidAssets | 469.00K | 169.00K | ||
| GoodwillAndOtherIntangibleAssets | 15.63M | 0.00 | ||
| NetPPE | 4.71M | 560.00K | 719.00K | 284.00K |
| AccumulatedDepreciation | -6.00K | -36.00K | ||
| GrossPPE | 4.71M | 560.00K | 719.00K | 320.00K |
| Leases | 26.00K | 15.00K | ||
| OtherProperties | 4.71M | 560.00K | 719.00K | 227.00K |
| MachineryFurnitureEquipment | 0.00 | 78.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 562.33M | 375.27M | 347.87M | 289.37M |
| OtherCurrentAssets | 4.37M | 2.35M | 1.01M | 1.01M |
| PrepaidAssets | 9.05M | 6.58M | 4.60M | 4.04M |
| Inventory | 3.32M | 0.00 | ||
| Receivables | 13.88M | 0.00 | ||
| AccountsReceivable | 13.88M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 531.72M | 366.35M | 342.27M | 284.31M |
| OtherShortTermInvestments | 406.75M | 135.56M | 257.01M | 0.00 |
| CashAndCashEquivalents | 124.97M | 230.78M | 85.26M | 284.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -152.38M | -150.08M | -109.90M | -56.54M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 178.18M | 161.41M | 161.61M | 296.80M |
| CapitalExpenditure | -74.27M | -3.22M | -26.00K | -8.00M |
| IncomeTaxPaidSupplementalData | 1.90M | 0.00 | 0.00 | |
| EndCashPosition | 124.97M | 230.78M | 85.26M | 284.31M |
| BeginningCashPosition | 230.78M | 85.26M | 284.31M | 43.73M |
| ChangesInCash | -105.82M | 145.52M | -199.05M | 240.58M |
| FinancingCashFlow | 203.29M | 164.00M | 165.90M | 297.12M |
| CashFlowFromContinuingFinancingActivities | 203.29M | 164.00M | 165.90M | 297.12M |
| ProceedsFromStockOptionExercised | 25.11M | 2.59M | 4.29M | 318.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | 129.76M | |
| PreferredStockIssuance | 0.00 | 0.00 | 129.76M | |
| NetCommonStockIssuance | 178.18M | 161.41M | 161.61M | 167.04M |
| CommonStockIssuance | 178.18M | 161.41M | 161.61M | 167.04M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -230.99M | 128.38M | -255.07M | -8.00M |
| CashFlowFromContinuingInvestingActivities | -230.99M | 128.38M | -255.07M | -8.00M |
| NetInvestmentPurchaseAndSale | -264.73M | 131.60M | -255.05M | 0.00 |
| SaleOfInvestment | 393.89M | 575.44M | 139.16M | 0.00 |
| PurchaseOfInvestment | -658.62M | -443.84M | -394.21M | 0.00 |
| NetIntangiblesPurchaseAndSale | 35.90M | -3.00M | 0.00 | -8.00M |
| SaleOfIntangibles | 108.00M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -72.10M | -3.00M | 0.00 | -8.00M |
| NetPPEPurchaseAndSale | -2.17M | -224.00K | -26.00K | 0.00 |
| PurchaseOfPPE | -2.17M | -224.00K | -26.00K | 0.00 |
| OperatingCashFlow | -78.11M | -146.85M | -109.87M | -48.54M |
| CashFlowFromContinuingOperatingActivities | -78.11M | -146.85M | -109.87M | -48.54M |
| ChangeInWorkingCapital | 26.48M | 9.42M | 6.56M | 2.69M |
| ChangeInOtherWorkingCapital | 4.79M | |||
| ChangeInOtherCurrentLiabilities | 488.00K | -405.00K | -347.00K | -182.00K |
| ChangeInPayablesAndAccruedExpense | 42.79M | 12.89M | 7.76M | 6.66M |
| ChangeInAccruedExpense | 42.10M | 10.57M | 9.24M | 5.11M |
| ChangeInPayable | 686.00K | 2.32M | -1.48M | 1.54M |
| ChangeInAccountPayable | 686.00K | 2.32M | -1.48M | 1.54M |
| ChangeInPrepaidAssets | -4.46M | -3.07M | -846.00K | -3.78M |
| ChangeInInventory | -3.24M | 0.00 | 0.00 | |
| ChangeInReceivables | -13.88M | 0.00 | 0.00 | |
| ChangesInAccountReceivables | -13.88M | 0.00 | 0.00 | |
| OtherNonCashItems | 55.00M | 3.00M | 8.00M | |
| StockBasedCompensation | 48.26M | 39.34M | 27.24M | 13.32M |
| AmortizationOfSecurities | -6.39M | -10.08M | -2.03M | 0.00 |
| DepreciationAmortizationDepletion | 2.03M | 383.00K | 531.00K | 199.00K |
| DepreciationAndAmortization | 2.03M | 383.00K | 531.00K | 199.00K |
| AmortizationCashFlow | 1.47M | 0.00 | 0.00 | |
| AmortizationOfIntangibles | 1.47M | 0.00 | 0.00 | |
| Depreciation | 559.00K | 383.00K | 531.00K | 199.00K |
| OperatingGainsLosses | -108.00M | |||
| GainLossOnSaleOfPPE | -108.00M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -95.50M | -188.92M | -142.18M | -72.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DAWN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|